Título : |
Glucagon like peptide 1 receptor agonists: a therapy for diabetes management |
Otros títulos : |
Agonistas del receptor péptido 1 similar al glucagón: una terapia para el control de la diabetes |
Tipo de documento : |
documento electrónico |
Autores : |
Natalia Andrea Rojas Henao, ; Elkyn Johan Granados Vega, |
Fecha de publicación : |
2018 |
Títulos uniformes : |
CES Medicina
|
Idioma : |
Inglés (eng) |
Palabras clave : |
Diabetes Mellitus Type 2 Glucagon-like peptide-1 Hypoglycemia Hemoglobin A glycosylated |
Resumen : |
Introduction: Glucagon-like peptide 1 agonists inhibit glucose-dependent glucagon secretion, decrease gastric emptying and appetite through neural mechanisms, contribute to glucose regulation and show reduction in glycated hemoglobin A. Methods: A bibliographic search was made on Medline® about pharmacology of the agonist glucagon-like peptide-1 receptor , Liraglutide, Lixisenatide, Albiglutide, Exenatide, Exenatide with long-acting release. Results: The GLP1 receptor agonist are agents involved with glycemic balance, weight loss induction and are associated with lower risk of hypoglycemia. They have shown efficacy in the treatment of hypoglycemia in patients with type-2 diabetes. Conclusions: GLP1 receptor agonist are part of the therapies for diabetes that have shown benefits in metabolic control, effectiveness in weight reduction and changes in glycated hemoglobin. More studies are needed to evaluate its long-term safety. |
Mención de responsabilidad : |
Natalia Andrea Rojas, Elkyn Johan Granados Vega |
DOI (Digital Object Identifier) : |
10.21615/cesmedicina.32.1.3 |
Derechos de uso : |
CC BY-NC-ND |
En línea : |
https://revistas.ces.edu.co/index.php/medicina/article/view/3983 |
Enlace permanente : |
https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4733 |
Glucagon like peptide 1 receptor agonists: a therapy for diabetes management = Agonistas del receptor péptido 1 similar al glucagón: una terapia para el control de la diabetes [documento electrónico] / Natalia Andrea Rojas Henao, ; Elkyn Johan Granados Vega, . - 2018. Obra : CES MedicinaIdioma : Inglés ( eng) Palabras clave : |
Diabetes Mellitus Type 2 Glucagon-like peptide-1 Hypoglycemia Hemoglobin A glycosylated |
Resumen : |
Introduction: Glucagon-like peptide 1 agonists inhibit glucose-dependent glucagon secretion, decrease gastric emptying and appetite through neural mechanisms, contribute to glucose regulation and show reduction in glycated hemoglobin A. Methods: A bibliographic search was made on Medline® about pharmacology of the agonist glucagon-like peptide-1 receptor , Liraglutide, Lixisenatide, Albiglutide, Exenatide, Exenatide with long-acting release. Results: The GLP1 receptor agonist are agents involved with glycemic balance, weight loss induction and are associated with lower risk of hypoglycemia. They have shown efficacy in the treatment of hypoglycemia in patients with type-2 diabetes. Conclusions: GLP1 receptor agonist are part of the therapies for diabetes that have shown benefits in metabolic control, effectiveness in weight reduction and changes in glycated hemoglobin. More studies are needed to evaluate its long-term safety. |
Mención de responsabilidad : |
Natalia Andrea Rojas, Elkyn Johan Granados Vega |
DOI (Digital Object Identifier) : |
10.21615/cesmedicina.32.1.3 |
Derechos de uso : |
CC BY-NC-ND |
En línea : |
https://revistas.ces.edu.co/index.php/medicina/article/view/3983 |
Enlace permanente : |
https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4733 |
| |